Lisa Boyette, MD, PhD oversees the late-phase MASH/MASLD Development Program at Eli Lilly and Company.  She is also an adjunct research faculty member of the Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh Medical Center.  Prior to joining Eli Lilly, Dr. Boyette most recently led MASH and cholestasis development programs at Gilead Sciences.

A PharmaVoice 100 honoree, Dr. Boyette was Founder-CEO of the nonprofit research organization Curable prior to entering the pharmaceutical industry. She spends most of her time developing medicines for hepatobiliary patient populations with serious unmet medical needs and raising awareness about the importance of clinical research in liver indications.  Dr. Boyette completed her Transplantation Immunology training at the Starzl Transplantation Institute, University of Pittsburgh, an IRTA Fellowship at NIAMS, National Institutes of Health, and a Mirzayan Policy Fellowship at the Institute of Medicine, National Academies of Science.  She received both her MD and PhD in Molecular Physiology and Biological Physics from the University of Virginia and earned a Bachelor of Science in Biomedical Engineering from Virginia Commonwealth University.